Optomed

3.955 EUR

-0.25 %

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

5,335 following

-0.25%

-2.71%

-17.26%

-41.75%

+6.46%

+31.18%

-64.37%

-13.65%

www.optomed.com/investors

Optomed is a medical technology company. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that is resold under different brands. The company operates worldwide, with the largest presence in the Nordic market. The customers consist of research institutes and hospitals. Optomed is headquartered in Oulu.

P/E (adj.) (24e)

-16.29

EV/EBIT (adj.) (24e)

-15.13

P/B (24e)

3.23

Dividend yield-% (24e)

Target price

5.50 EUR

Recommendation

Buy

Updated

18.11.2024

NASDAQ Helsinki

OPTOMED

Daily low / high price

3.88 / 4.05 EUR

Market cap

77.89M EUR

Turnover

116.36K EUR

Volume

29K

Business risk

Valuation risk

Current

Juha Kinnunen

Analyst

Latest videos

Health Technology & Pharmaceutical Developer Night – Tuesday, Dec. 13 at 4:00 pm EET

13.12.2022

Financial calendar

Annual report

13.02.2025

Interim report

06.05.2025

Interim report

07.08.2025

Interim report

06.11.2025

Major Owners
Source: Millistream Market Data AB

Owner	Capital	Votes
OP-Finland Small Cap	7.3 %	7.3 %
Skandinaviska Enskilda Banken Ab (publ) Helsinki Branch	5.9 %	5.9 %

Premium

This content is for our Premium customers only.

Learn more

Insider Transactions

Insider	Date	Total value
Markku Myllylä	09.08.2024	76,536EUR
Laura Piila	07.08.2024	98,000EUR

Premium

This content is for our Premium customers only.

Learn more

Forum updates

Stay up-to-date with the latest talk about Optomed

Read the full thread

Visit the forum

linkedin.com Optomed US on LinkedIn: #optomedus #aeyehealth #californiacareforce... We’re thrilled to have partnered with California CareForce at their recent free healthcare clinic in Fresno, CA! Optomed’s Aurora AEYE handheld fundus camera…

Tobias

2 days ago💙 34

I am excited to announce our latest pilot implementation with Prestige Medical Group, Georgia’s leading primary care practice! This partnership marks another step forward in our mission to deliver a Human+AI solution that provides the best care to #diabetic patients. These patients deserve nothing less than quality care delivered at their convenience and comfort. linkedin.com Awais Bajwa on LinkedIn: #diabetic #blindness #ai #blindnessprevention... I am excited to announce our latest pilot implementation with Prestige Medical Group, Georgia's leading primary care practice! This partnership marks another… Prestige Medical Group Who is Prestige - Prestige Medical Group [vc_row type=”full_width_background” full_screen_row_position=”middle” column_margin=”default” equal_height=”yes” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” bg_color=”#224162″ scene_position=”center”... Est. reading time: 2 minutes

BossoB

2 days ago💙 32

linkedin.com Optomed Plc on LinkedIn: #optomedaurora #optomed #epomec #screening #ai... Optomed is heading to EPOMEC in Dubai from December 5-7. We are thrilled to showcase #OptomedAurora with AI integration, designed to provide retinal screening… Ja messua pukkaa… tällä kertaa Dubai. Nyt on tekemisen meininkiä. Mites se menikään; ensin tulee työ ja sitten?

Mr. Stock

2 days ago💙 29

Tämä kommentti kertoo paljon: Mallika Kapur • 3rd+ CEO at NextGen eSolutions (P) Ltd. ](Mallika Kapur - Aimil Ltd. | LinkedIn) Excited to be a part of this event with you Petri Huhtinen. OCI India, thank you for organising this - there is a burning need to screen for Diabetic Retinopathy, and soon.

Cujo Jr.

2 days ago💙 28

linkedin.com Petri Huhtinen on LinkedIn: #diabeticretinopathy #screening... Thank you Dr. Mallika Kapur and the team for giving me this opportunity to speak about #diabeticretinopathy and #screening without forgetting… And meanwhile in India

Mr. Stock

2 days ago💙 25

linkedin.com AEYE Health on LinkedIn: World Diabetes Day: The Startups Improving Diabetes... 🎉 Excited to share that AEYE Health has been featured in TechRound’s article, "World Diabetes Day: The Startups Improving Diabetes Care"! We’re honored to be…

marmot76

yesterday💙 23

Eiköhän tuolla varastossa ole normaalisti ~1kvartaalin menekkiä vastaava inventaario Aurora IQ:ta, jotta varaston arvo ei nouse liikaaa. Epäilemättä tuo viimeisin isompi tilaus ei tullut “puskista” vaan sitä osattiin odottaa ja täydennystilaus varastoon on tehty jo hyvissä ajoin. Todnäk varasto on nyt ja jatkossa vielä enemmän Aurora AEYE:hin painottuva.

Sheikki

11/19/2024, 1:22 PM💙 10

Income statement

	2020	2021	2022	2023	2024e	2025e	2026e	2027e
Revenue	13.0	14.9	14.7	15.1	15.0	20.2	27.5	34.7
growth-%	-13.1 %	14.1 %	-1.3 %	3.0 %	-0.4 %	34.5 %	35.7 %	26.3 %
EBITDA	-0.7	-2.0	-2.0	-1.8	-2.2	-1.1	4.0	8.6
EBIT (adj.)	-2.9	-4.8	-5.1	-3.7	-4.6	-4.2	-1.5	2.1
EBIT	-2.9	-4.8	-5.1	-4.0	-4.6	-4.2	-1.5	2.1
Profit before taxes	-3.2	-4.3	-5.6	-4.5	-4.7	-4.5	-1.7	1.8
Net income	-3.2	-4.2	-5.5	-4.4	-4.7	-4.5	-1.7	1.8
EPS (adj.)	-0.24	-0.31	-0.38	-0.25	-0.24	-0.23	-0.09	0.09
growth-%
Dividend	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend ratio

Login required

This content is only available for logged in users

Create account

Profitability and return on capital

	2020	2021	2022	2023	2024e	2025e	2026e	2027e
EBITDA-%	-5.6 %	-13.5 %	-13.3 %	-11.8 %	-14.5 %	-5.2 %	14.7 %	24.8 %
EBIT-% (adj.)	-22.3 %	-32.2 %	-34.8 %	-24.3 %	-30.8 %	-21.0 %	-5.4 %	6.1 %
EBIT-%	-22.3 %	-32.2 %	-34.8 %	-26.3 %	-30.8 %	-21.0 %	-5.4 %	6.1 %
ROE	-14.9 %	-22.9 %	-29.3 %	-21.8 %	-21.3 %	-21.2 %	-9.4 %	9.9 %
ROI	-9.8 %	-18.9 %	-20.5 %	-15.5 %	-17.5 %	-16.0 %	-5.7 %	8.3 %

Login required

This content is only available for logged in users

Create account

Valuation

	2020	2021	2022	2023	2024e	2025e	2026e	2027e
Share price (EUR)	7.10	9.80	3.75	3.72	3.96	3.96	3.96	3.96
Shares	13.3	13.6	16.2	17.8	19.3	19.3	19.3	19.3
Market cap	94.2	133.1	60.5	66.1	76.3	76.3	76.3	76.3
Enterprise value	90.1	133.3	57.3	62.4	70.1	77.1	80.1	79.6
EV/S	6.9	9.0	3.9	4.1	4.7	3.8	2.9	2.3
EV/EBITDA	-	-	-	-	-	-	19.9	9.3
EV/EBIT (adj.)	-	-	-	-	-	-	-	37.4
EV/EBIT	-	-	-	-	-	-	-	37.4
P/E (adj.)	-	-	-	-	-	-	-	42.4
P/E	-	-	-	-	-	-	-	42.4
P/B	4.7	7.8	3.0	3.2	3.2	4.0	4.4	4.0
P/S	7.2	9.0	4.1	4.4	5.1	3.8	2.8	2.2
Dividend yield
Equity ratio	64.6 %	58.8 %	65.0 %	70.0 %	72.3 %	63.1 %	52.5 %	50.2 %
Gearing ratio	-20.4 %	1.2 %	-16.0 %	-18.5 %	-26.2 %	4.3 %	21.9 %	17.7 %

Login required

This content is only available for logged in users

Create account

Quarter data

	Q4/23	2023	Q1/24	Q2/24	Q3/24	Q4/24e	2024e	Q1/25e	Q2/25e
Revenue	3.7	15.1	3.3	3.5	3.1	5.1	15.0	4.1	4.8
EBITDA	-0.8	-1.8	-0.6	-1.2	-0.8	0.5	-2.2	-0.4	-0.2
EBIT	-1.3	-4.0	-1.2	-1.9	-1.4	-0.2	-4.6	-1.1	-1.0
Profit before taxes	-1.5	-4.5	-1.1	-1.8	-1.6	-0.2	-4.7	-1.2	-1.1
Net income	-1.5	-4.4	-1.1	-1.8	-1.6	-0.2	-4.7	-1.2	-1.1